Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.
Chang Elma E, Goldberg Jeffrey L
AI Summary
This review highlights glaucoma's neurodegenerative nature beyond IOP, identifying new therapeutic targets for RGC survival, regeneration, and function to improve patient outcomes.
Abstract
Glaucoma is a progressive neurodegenerative disease of retinal ganglion cells (RGCs) associated with characteristic axon degeneration in the optic nerve. Clinically, our only method of slowing glaucomatous loss of vision is to reduce intraocular pressure (IOP), but lowering IOP is only partially effective and does not address the underlying susceptibility of RGCs to degeneration. We review the recent steps forward in our understanding of the pathophysiology of glaucoma and discuss how this understanding has given us a next generation of therapeutic targets by which to maintain RGC survival, protect or rebuild RGC connections in the retina and brain, and enhance RGC function.
MeSH Terms
Shields Classification
Related Articles5
A Protective Eye Shield Reduces Limbal Strain and Its Variability During Simulated Sleep in Adults With Glaucoma.
Randomized Controlled TrialNeuroprotection in glaucoma: recent advances and clinical translation.
ReviewGlaucoma: now and beyond.
ReviewOcular blood flow in the progression and therapy of glaucoma. Symposium proceedings. St. Paul de Vence, France, March 10-13, 1993.
ReviewModifiable factors in the management of glaucoma: a systematic review of current evidence.
Systematic ReviewIs this article assigned to the wrong chapter(s)? Let us know.